ArticleCancer immunology, immunotherapy : CII2021

Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.

Takeshi Ishikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.